The Halifax-based company saw heightened engagement at the ISTH 2026 conference in Paris, where clinicians sought clarity on measuring factor levels against emerging bispecific antibodies. CEO Paul Empey noted that the firm’s bovine Chromogenic Factor VIII assay is becoming a critical resource for labs navigating the transition from traditional replacement products to newer mimetics. Beyond its diagnostic offerings, the company presented research on lupus anticoagulant assays and modified testing methods for inhibitor titers, further cementing its role in coagulation research.
Precision BioLogic Gains Traction in Hemostasis Testing Market
As Novo Nordisk moves Mim8 through the FDA approval process, demand is surging for specialized diagnostic tools capable of measuring Factor VIII in the presence of next-generation therapies. Precision BioLogic, alongside subsidiaries Affinity Biologicals and George King Bio-Medical, is positioning its chromogenic assays to meet this clinical shift.
Following the Paris event, the organization maintained its momentum with a tour of major medical forums, including the ADLM 2026 meeting in Anaheim and the NBDF Bleeding Disorders Conference in Orlando. These engagements highlighted the integration of the company’s three branches: Precision BioLogic’s diagnostic reach, Affinity Biologicals’ manufacturing capabilities, and George King Bio-Medical’s deep ties to patient communities. By aligning specialized manufacturing with direct clinical support, the group is scaling its influence across the global hemostasis sector.
Comments (0)
No comments yet. Be the first!